Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy

Epilepsy Clinical Trial

Official title:

Open-Label Study to Assess the Safety and Tolerability of Intravenous Carbamazepine as Short-Term Replacement of Oral Carbamazepine in Adult Patients With Epilepsy

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01128959
• Other study ID #: 13181A
• Status: Completed
• Phase: Phase 3
• First received: May 21, 2010
• Last updated: December 14, 2017
• Start date: June 2010
• Est. completion date: January 2013

Study information

• Verified date: December 2017
• Source: Lundbeck LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and tolerability of intravenous (IV) carbamazepine (CBZ) administered as multiple 15 minute infusions and a single 5 minute infusion to adult patients with epilepsy on stable higher doses of oral CBZ.

Description:

This was a phase III, multicenter, open-label study designed to assess the safety and tolerability of intravenously administered CBZ in adult patients with epilepsy. This study included a 28 day Lead-in Period, a Confinement Period (up to 7 days and 6 nights) and a 28 day Follow-up Period.

Patients began confinement on Day -1 of the trial, continuing to take their oral CBZ as prescribed by the investigator. On the morning of Day 0, Day 4, and Day 17, patients began the 24hr urine collection for evaluation of urinary biomarkers. All patients temporarily discontinued their prescribed oral CBZ and begin IV CBZ administration on the morning of Day 1, continuing administrations every 6 hours (Q6h) through the morning of Day 4.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 108
• Est. completion date: January 2013
• Est. primary completion date: January 2013
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. The patient or legal representative must be able to read, understand, sign and date the IRB approved Informed Consent Form and HIPAA Authorization prior to study participation.

2. The patient is a man or a non-pregnant woman who is at least 18 years of age.

3. If a woman:

• Patient is either not of childbearing potential, defined as postmenopausal for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomay or hysterectomy), or if childbearing potential, must comply with a method of birth control acceptable to the investigator during the study, for at least 28 days prior to Day 1 and for 28 days following completion of the study.

• Patient is not breastfeeding.

• Patient of childbearing potential must have a negative serum pregnancy test at Day -28 and a negative urine pregnancy test or serum pregnancy test at Day -1.

4. The patient is diagnosed with any of the approved epilepsy indications for CBZ:

• Partial seizures with complex symptomatology (psychomotor, temporal lobe)

• Generalised tonic clonic seizures (GTCS) (grand mal): myoclonic, clonic, tonic, tonic-clonic, atonic

• Mixed seizure patterns that include the above, or other partial or generalised seizures (except absence seizures - please see exclusion point number 12)

5. The patient is receiving a stable dose of oral CBZ (tablet or capsule formulation) of 1200 mg/day to 2000 mg/day, for a minimum of 14 days prior to Day -28.

6. The patient is receiving a constant dose of all other concomitant medications used for chronic conditions, (including OTC medications and herbal supplements) for a minimum of 28 days prior to Day 1.

7. The patient is not expected to have any change in his/her baseline AED treatment during the treatment period.

8. The patient is able to comply with maintaining an accurate Seizure and antiepileptic drug diary.

9. The patient is able to comply with all study procedures including complying with protocol determined dosing intervals, confinement at the investigative site for up to 6 nights and 7 days, and agrees to participate in the entire study.

Exclusion Criteria:

1. The patient has a known hypersensitivity to CBZ, Captisol, or to any of the tricyclic compounds, such as amitriptyline, trimipramine, imipramine; oxacarbazepine, phenytoin, or their analogues or metabolites.

2. The patient has a history of previous bone marrow depression.

3. The patient has a history of intolerance to IV administration of medication.

4. The patient is pregnant or lactating.

5. The patient is being treated with a monoamine oxidase (MAO) inhibitor.

6. The patient is using oral, intramuscular, or any other hormone delivery method as their primary form of birth control.

7. The patient has an ECG with corrected QT interval by Fridericia's correction formula (QTcF) greater than 450 msec at Screening or Day -1.

8. The patient has a screening ALT, AST or bilirubin >=3 times the upper limit of normal.

9. The patient has an estimated ClCR (based of Cockcroft-Gault) of <50 ml/min.

10. The patient has had a clinically significant illness/infection or has had any surgical procedure within 30 days prior to Screening.

11. The patient has a significant history of cardiac, renal, neurologic (other than epilepsy), psychiatric, oncologic, endocrinologic, metabolic, or hepatic disease, which would adversely affect their participation in this study.

12. The patient is receiving oral CBZ for absence seizures.

13. The patient has had an episode of status epilepticus within 4 weeks of Screening.

14. The patient has a history of severe or serious adverse reactions to CBZ (for example, aplastic anemia, agranulocytosis, SJS.

15. The patient has taken or used any investigational drug or device in the 30 days prior to Screening.

16. The patient has previously been administered IV CBZ in a previous clinical trial (for example OV-1015).

17. The patient has a urine toxicology screen positive for phencyclidine, benzodiazepines (unless due to the patient's concomitant AEDs), cannabinoids, cocaine, amphetamines, opiates, barbiturates (unless due to the patient's concomitant AEDs), or alcohol at Screening or Day -1.

18. The patient has had a diagnosis of drug or alcohol abuse within the past year prior to Screening.

19. The patient has had significant blood loss (>500 mL) or donation within 14 days of Screening.

20. The patient has a history of poor oral CBZ compliance.

21. The patient is participating in a weight loss or nicotine cessation program.

22. The patient has a history of increased intraocular pressure or is on medication for glaucoma.

23. The patient is considered by the investigator to be an unsuitable candidate for the study, which may include an increase in the frequency, severity and duration of seizures during the Pre-Treatment Period (Days -28-0).

24. The patient has previously participated in this study.

25. The patient is a member of the site personnel or their immediate families.

Related Conditions & MeSH terms

• Epilepsy

Intervention

Drug:
• Intravenous Carbamazepine (IV CBZ)
10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.

Locations

Country	Name	City	State
United States	Mid-Atlantic Epilepsy and Sleep Center	Bethesda	Maryland
United States	Beth Israel Deaconess Medical Center	Boston	Massachusetts
United States	Montefiore Medicical Center	Bronx	New York
United States	Medical University of South Carolina	Charleston	South Carolina
United States	University of Virginia	Charlottesville	Virginia
United States	The Comprehensive Epilepsy Care Center for Children and Adults	Chesterfield	Missouri
United States	University of Illinois at Chicago	Chicago	Illinois
United States	Cleveland Clinic	Cleveland	Ohio
United States	Neurological Clinic of Texas, P.A.	Dallas	Texas
United States	Denver Health and Hospital Authority	Denver	Colorado
United States	Leonard J. Chabert Medical Center	Houma	Louisiana
United States	Clinical Trials Incorporated	Little Rock	Arkansas
United States	Louisiana Research Associates	New Orleans	Louisiana
United States	Ochsner Clinic Foundation	New Orleans	Louisiana
United States	Columbia University Medical Center: Dept of Neurology	New York	New York
United States	Langone Medical Center NYU Comprehensive Epilepsy Center	New York	New York
United States	Temple University Health systems	Philadelphia	Pennsylvania
United States	Mayo Clinic Arizona	Phoenix	Arizona
United States	VCU Medical Center	Richmond	Virginia
United States	University of Rochester	Rochester	New York
United States	University of Minnesota & Prism Research	Saint Paul	Minnesota
United States	Southern illinois University School of Medicine	Springfield	Illinois
United States	SUNY Upstate Medical University	Syracuse	New York
United States	University of South Florida	Tampa	Florida
United States	Scott & White Memorial Hospital	Temple	Texas
United States	Collaborative Neuroscience Network, Inc.	Torrance	California
United States	Via Christi Epilepsy Center	Wichita	Kansas
United States	Central DuPage Hospital	Winfield	Illinois
United States	Wake Forest University Health Sciences	Winston-Salem	North Carolina

Sponsors (4)

Lead Sponsor	Collaborator
Lundbeck LLC	ICON Clinical Research, Ligand Pharmaceuticals, Quintiles, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Adverse Events		Baseline to after last iv dose on day 4